BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Roflumilast (Zoryve) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Roflumilast (Zoryve)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07725822-1479@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Roflumilast (Zoryve): Phase 4 readout est. (NCT07725822)
DESCRIPTION:Roflumilast (Zoryve)\, phase 4\, Psoriasis.\nStudy: An Open Lab
 el Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chr
 onic Plaque and Nail Psoriasis\nEstimated primary completion: July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/roflumilast-zoryve#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0772582
 2
URL:https://assetmemo.bio/drug/roflumilast-zoryve#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560618-1479@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Roflumilast (Zoryve): Phase 4 readout est. (NCT07560618)
DESCRIPTION:Roflumilast (Zoryve)\, phase 4\, Atopic Dermatitis.\nStudy: Obt
 aining Descriptive Classifications of Pruritus and Assessing Change in Pru
 ritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cr
 eam.\nEstimated primary completion: August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/roflumilast-zoryve#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07560618
URL:https://assetmemo.bio/drug/roflumilast-zoryve#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07916480-1479@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280427
DTEND;VALUE=DATE:20280428
SUMMARY:Roflumilast (Zoryve): Phase 3 readout est. (NCT07916480)
DESCRIPTION:Roflumilast (Zoryve)\, phase 3\, Atopic Dermatitis.\nStudy: Rof
 lumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis\nEstimated pr
 imary completion: 27 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/roflumilast-zoryve#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07916480
URL:https://assetmemo.bio/drug/roflumilast-zoryve#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
